Novel treatment combination improves progression-free survival in most common form of metastatic breast cancer
Patients with estrogen receptor-positive (ER+), HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared with a standard combination approach. These findings, from the phase 3 evERA Breast…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
New fluorescent paper strips make vitamin B12 testing simpler
United Kingdom
-
Robotic assisted hip and knee replacements shows no clear benefit over conventional methods
United Kingdom
-
Before the first bite: A missing gut protein may set the stage for peanut allergy
United Kingdom
-
Discovery explains how immune cells target DNA mutations to improve antibodies
United Kingdom
-
Gut bacterial metabolite worsens brain damage after stroke, study finds
United Kingdom
-
New framework maps depression symptoms to unique brain circuits
United Kingdom
-
Sleep hours miss part of story: Young adults lose sleep quality, not hours, amid heat, noise and light
United Kingdom
-
New recommendations for serrated polyposis syndrome
United Kingdom